Type I interferons in tuberculosis: Foe and occasionally friend by Moreira-Teixeira, L et al.
REVIEW
https://doi.org/10.1084/jem.20180325 1
J. Exp. Med. 2018
Rockefeller University Press
Tuberculosis remains one of the leading causes of mortality worldwide, and, despite its clinical significance, there are still 
significant gaps in our understanding of pathogenic and protective mechanisms triggered by Mycobacterium tuberculosis 
infection. Type I interferons (IFN) regulate a broad family of genes that either stimulate or inhibit immune function, 
having both host-protective and detrimental effects, and exhibit well-characterized antiviral activity. Transcriptional 
studies have uncovered a potential deleterious role for type I IFN in active tuberculosis. Since then, additional studies 
in human tuberculosis and experimental mouse models of M. tuberculosis infection support the concept that type I IFN 
promotes both bacterial expansion and disease pathogenesis. More recently, studies in a different setting have suggested 
a putative protective role for type I IFN. In this study, we discuss the mechanistic and contextual factors that determine 
the detrimental versus beneficial outcomes of type I IFN induction during M. tuberculosis infection, from human disease to 
experimental mouse models of tuberculosis.
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Introduction
Although cytokines play critical roles in host defense and 
immune homeostasis, they can also be key mediators of inflam-
matory pathology. This paradoxical aspect of cytokine biology is 
perhaps best exemplified in the dichotomous functions of type 
I IFN in health and disease. The type I IFN family is a multigene 
cytokine family that encodes numerous partially homologous 
IFN-α subtypes, a single IFN-β, and several other poorly defined 
single genes products (Pestka et al., 2004). All type I IFN share 
a ubiquitously expressed heterodimeric receptor composed of 
the subunits IFN AR1 and IFN AR2, which signal through STAT1 
and STAT2 to activate a broad family of IFN-stimulated genes 
(ISGs; Pestka et al., 2004; Ivashkiv and Donlin, 2014). Dominant 
IFN AR1 expression has been shown to favor IFN-β ligation and 
activation of the protein kinase B (also known as Akt) pathway 
over the classical JAK–STAT pathway (de Weerd et al., 2013). ISGs 
either stimulate or inhibit immune function and in so doing have 
host-protective or detrimental effects. Thus, although type I IFN 
is well known for its antiviral activity and stimulation of effector 
T cell responses (Yan and Chen, 2012; Crouse et al., 2015), it has 
also been implicated in autoimmune diseases (Hall and Rosen, 
2010) and exacerbation of bacterial and even certain viral infec-
tions (Decker et al., 2005; Trinchieri, 2010; Davidson et al., 2015; 
McNab et al., 2015).
The host beneficial protective effects of type I IFN have been 
most thoroughly studied in viral infections where these cyto-
kines stimulate the production of innate antiviral proteins and 
promote effector CD8+ T cell responses (Crouse et al., 2015). The 
deleterious effects of type I IFN seen in autoimmune diseases 
such as lupus or in the genetically based interferonopathies 
appear to stem largely from dysregulated cytokine synthesis 
(Banchereau and Pascual, 2006; Crow, 2015). Nevertheless, cyto-
kine overproduction does not provide a unifying explanation for 
the deleterious activity of type I IFN in infections with bacteria 
such as Listeria monocytogenes, Brucella abortus, and Staphylo-
coccus aureus (McNab et al., 2015; Stifter and Feng, 2015).
The present review focuses on the role of type I IFN in the 
immune response to Mycobacterium tuberculosis. This topic 
has received great attention (O’Garra et al., 2013; Mayer-Barber 
and Sher, 2015; Donovan et al., 2017; Sabir et al., 2017) both 
because of the global public health importance of this pathogen 
and the now numerous studies linking type I IFN expression 
with tuberculosis. However, recent data suggest that even in the 
prominent example of tuberculosis, the “foe”-like properties of 
type I IFN are not ironclad and the same cytokines can display 
“friendly” protective functions under different settings of host–
pathogen encounter. Deciphering the mechanisms underlying 
these opposing activities of type I IFN in tuberculosis should 
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contribute enormously to our understanding of the pathogen-
esis of this important disease while providing new insights into 
how this major cytokine pathway can be manipulated to ensure 
beneficial rather than deleterious outcomes for the host.
Role of cytokines in the immune response in tuberculosis
Despite being one of the oldest diseases, tuberculosis remains 
a devastating public health problem. Worldwide, 6.3 million 
new cases and 1.67 million deaths (of which 0.37 million were 
in HIV-positive coinfected individuals) were reported in 2016 
alone (World Health Organization, 2017). Although most individ-
uals exposed to M. tuberculosis generate an effective immune 
response and remain clinically asymptomatic (latent infection), 
∼10% of the infected individuals will progress to active disease 
at some stage of their lifetime, presenting with clinical signs and 
symptoms of tuberculosis and, in a significant proportion of 
patients, cultivable bacilli in the sputum (Lawn and Zumla, 2011; 
O’Garra et al., 2013; Getahun et al., 2015). Several mechanisms 
have been described that result in the development of a protec-
tive immune response that controls infection (Flynn and Chan, 
2001; North and Jung, 2004; Cooper, 2009; O’Garra et al., 2013); 
however, the host immune mechanisms underlying progression 
to active disease remain poorly understood.
The role of cytokines in host protection against M. tubercu-
losis infection is well established and was first demonstrated in 
experimental mouse models of infection that established criti-
cal roles for IFN-γ (Cooper et al., 1993; Flynn et al., 1993), TNF-α 
(Flynn et al., 1995a), and IL-12 (Cooper et al., 1995, 1997; Flynn 
et al., 1995b) in controlling infection. Importantly, these early 
discoveries were corroborated by studies of human tuberculosis 
establishing the requirement of the same cytokines for protec-
tion. Patients with rheumatoid arthritis or Crohn’s disease who 
were latently infected with M. tuberculosis, when treated with 
anti–TNF-α antibodies or soluble receptor for TNF, showed an 
increased rate of progression to active tuberculosis (Keane et al., 
2001), corroborating a critical role for TNF-α in human tubercu-
losis. Moreover, human Mendelian susceptibility to mycobacterial 
disease resulting from deficient IL-12 or IFN-γ signaling confers 
high susceptibility to M. tuberculosis and other mycobacterial 
infections (Newport et al., 1996; Altare et al., 1998; de Jong et al., 
1998; Jouanguy et al., 1999; Fortin et al., 2007). Finally, it is well 
known that HIV-positive individuals with reduced CD4+ T cells, 
the main source of IFN-γ during M. tuberculosis infection, also 
display increased susceptibility to tuberculosis (Post et al., 1995). 
The mechanisms underlying the role of these cytokines was later 
described as an IL-12/IFN-γ axis in which IL-12, produced early in 
infection by APCs, promotes the differentiation of CD4+ T helper 1 
(Th1) cells and IFN-γ production. IFN-γ further activates macro-
phages to produce TNF-α and other protective cytokines, promot-
ing intracellular killing of the pathogen through the production 
of reactive oxygen and nitrogen species (Flynn and Chan, 2001; 
North and Jung, 2004; Cooper, 2009; O’Garra et al., 2013).
Type I IFN–inducible transcriptional signature in 
human tuberculosis
In contrast to the now well-established protective function of 
IFN-γ, the pathogenic role of type I IFN in tuberculosis has only 
recently been appreciated. The first evidence revealing a role for 
type I IFN in the pathogenesis of human tuberculosis was pro-
vided a few years ago by a transcriptomic study of patients with 
active disease and latently infected or healthy individuals from 
the UK and South Africa (Berry et al., 2010). Blood transcrip-
tional profiles of patients with active tuberculosis were domi-
nated by a type I IFN-inducible gene signature that correlated 
with the extent of lung radiographic disease and diminished with 
successful treatment (Berry et al., 2010). Several other studies 
have since verified these findings in additional patient cohorts 
from different geographic regions with diverse host genetic and 
tuberculosis epidemiological backgrounds (Maertzdorf et al., 
2011a,b, 2012; Bloom et al., 2012, 2013; Ottenhoff et al., 2012; 
Cliff et al., 2013; Roe et al., 2016; Zak et al., 2016; Sambarey et 
al., 2017b; Singhania et al., 2017; Esmail et al., 2018; Table 1). In 
addition, integration and meta-analysis of diverse human tuber-
culosis datasets confirmed the reproducibility of the type I IFN–
inducible blood transcriptional signature in human tuberculosis 
(Joosten et al., 2013; Blankley et al., 2016; Sambarey et al., 2017a; 
Singhania et al., 2017; Table 1). Analysis of purified cells from 
the blood of patients with active disease showed overexpression 
of IFN-inducible genes in neutrophils and monocytes, but not in 
CD4+ or CD8+ T cells (Berry et al., 2010; Bloom et al., 2013), sug-
gesting that overactivation of monocytes and neutrophils by type 
I IFN during infection may contribute to disease pathogenesis.
Similar findings have since been observed in other mycobac-
terial infections. In human leprosy, caused by Myobacterium 
leprae, type I IFN and their downstream genes, were preferen-
tially expressed in lesions of the disseminated and progressive 
lepromatous form at the site of disease, whereas IFN-γ and its 
downstream genes were preferentially expressed in the lesions 
from patients with the self-healing tuberculoid form (Teles et 
al., 2013). Overexpression of IFN-inducible genes in blood has 
also been reported in patients with other pulmonary diseases 
such as sarcoidosis and acute influenza infection but has not 
been detected in other bacterial infections (Berry et al., 2010; 
Maertzdorf et al., 2012; Bloom et al., 2013; Singhania et al., 2017). 
However, distinct gene patterns have been detected between 
tuberculosis and sarcoidosis (Bloom et al., 2013) and tuberculosis 
and influenza infection (Singhania et al., 2017).
In tuberculosis, overexpression of IFN response genes, includ-
ing STAT1, IFITs, GBPs, MX1, OAS1, IRF1, and other genes, were 
also detected early in tuberculosis contacts who progressed to 
active disease (Zak et al., 2016; Scriba et al., 2017; Singhania et 
al., 2017; Esmail et al., 2018), suggesting that peripheral activa-
tion of the type I IFN response precedes the onset of active dis-
ease and clinical manifestations of tuberculosis. These changes 
apparently preceded the up-regulation of other innate immune 
responses and down-regulation of genes associated with specific 
lymphocyte cell populations (Scriba et al., 2017; Singhania et al., 
2017), although this conclusion requires more detailed studies. 
The type I IFN–inducible signature was also present in 10–25% 
of latently infected patients who are asymptomatic (Berry et al., 
2010; Singhania et al., 2017), suggesting that these patients may 
be at the highest risk to progress to active disease.
Several clinical studies have reported reactivation of tuber-
culosis in patients undergoing IFN-α based therapy for chronic 
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viral hepatitis (Sabbatani et al., 2006; Farah and Awad, 2007; 
Telesca et al., 2007; Belkahla et al., 2010; Guardigni et al., 2012; 
Abutidze et al., 2016; de Oliveira Uehara et al., 2016; Matsuoka et 
al., 2016). In addition, a very recent study showed that impaired 
type I IFN signaling due to a rare East Asian functional mutation 
in the IFN AR1 gene was associated with increased resistance to 
tuberculosis (Zhang et al., 2018). As the control population con-
sisted of healthy individuals, it is presently unclear whether this 
polymorphism influences susceptibility to infection as opposed 
to disease progression in latent infected individuals. In contrast, 
patients with an inherited deficiency in the gene encoding ISG15, 
who displayed immunological and clinical signs of enhanced 
type I IFN responses (Zhang et al., 2015), were shown to be more 
susceptible to mycobacterial infections (Bogunovic et al., 2012). 
Together, these findings provide strong evidence that type I IFN 
signaling correlates with impaired control of M. tuberculosis and 
Table 1. Type I IFN–inducible blood transcriptional signature in human tuberculosis
Original  
study
Geographic 
location
Sample 
type
Cohort size ● Type I IFN signature shown in 
original study
o Type I IFN signature reported in subsequent 
analysis
Active 
disease
Correlated 
radiographical 
disease
Treatment 
response
Joosten et 
al., 2013
Blankley et 
al., 2016
Sambarey et 
al., 2017a
Singhania 
et al., 2017
Jacobsen et al., 
2007
Germany PBMCs Active TB (n = 9);  
LTBI (n = 9)
o
Mistry et al., 
2007
South Africa Whole blood Active, recurrent, or cured 
TB; LTBI (n = 10/group)
o
Berry et al., 
2010a
UK Whole blood 
(and sorted 
cells)
Active TB (n = 21);  
LTBI (n = 21); HCs (n = 12)
● ● ● o o o o
South Africa Whole blood Active TB (n = 20);  
LTBI (n = 31)
● o o o o
Maertzdorf et al., 
2011a
South Africa Whole blood Active TB (n = 46);  
LTBI (n = 25); HC (n = 37)
● o o
Maertzdorf et al., 
2011b
The Gambia Whole blood Active TB (n = 33);  
LTBI (n = 34); HC (n = 9)
● o
Bloom et al., 
2012
South Africa Whole blood active TB (n = 33);  
LTBI (n = 34); HC (n = 9)
● ● o o
Maertzdorf et al., 
2012
Germany Whole blood Active TB (n = 8);  
LTBI (n = 4); HC (n = 14)
● o o
Ottenhoff et al., 
2012
Indonesia PBMCs Active TB over time during 
treatment (n = 23);  
HC (n = 23)
● ● o o
Cliff et al., 2013 South Africa Whole blood Active TB over time during 
treatment (n = 27)
● ● o o o
Bloom et al., 
2013
UK Whole blood 
(and sorted 
cells)
Active TB (n = 35);  
HCs (n = 113)
● o o o
Kaforou et al., 
2013
South Africa, 
Malawi
Whole blood Active TB (HIV−/+; n = 195); 
LTBI (HIV−/+; n = 167)
o o
Cai et al., 2014 China PBMCs active TB (n = 9);  
LTBI (n = 6); HC (n = 6)
o
Anderson et al., 
2014
Kenya Whole blood Active TB (n = 79);  
LTBI (n = 14)
o
South Africa, 
Malawi
Active TB (n = 110);  
LTBI (n = 54)
o
Roe et al., 2016 UK Whole blood Active TB (n = 46); 
postrecovery (n = 31)
● ●
Zak et al., 2016 South Africa Whole blood Progressors (n = 40); 
nonprogressors (n = 104)
● o
Sambarey et al., 
2017b
India Whole blood Active TB (n = 19);  
LTBI (n = 13); HCs (n = 15)
●
Singhania et al., 
2017
UK Whole blood Active TB (n = 53);  
LTBI (n = 49); HCs (n = 50)
●
Esmail et al., 
2018
South Africa Whole blood Active TB (n = 15); 
subclinical TB (n = 10); 
latent TB (n = 25)
●
Type I IFN signature reported in original study (●) and/or in subsequent analysis by others (o). HC, healthy control; LTBI, latent tuberculosis infection; 
PBMC, peripheral blood mononuclear cell; TB, tuberculosis.
aOriginal study providing the first data in human disease to support a role for type I IFN in the pathogenesis of tuberculosis. 
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other mycobacterial infections and underlies an increased risk of 
tuberculosis in humans.
Foe-like pathogenic role of high and sustained type I IFN in 
tuberculosis: Evidence from mouse models
Following on from the observations in human tuberculosis, 
whole-genome blood transcriptional profiling in animal mod-
els of tuberculosis have since shown up-regulation of type I IFN 
response related genes in response to M. tuberculosis infec-
tion in both nonhuman primates (Gideon et al., 2016) and mice 
(Domaszewska et al., 2017). However, different effects of type I 
IFN in either protection or pathogenesis in experimental models 
of tuberculosis have been reported as we discuss herein. Several 
studies have reported reduced bacterial loads (Ordway et al., 
2007; Stanley et al., 2007; Mayer-Barber et al., 2011; Dorhoi et al., 
2014) and/or improved host survival (Manca et al., 2005; Dorhoi 
et al., 2014; Kimmey et al., 2017) upon M. tuberculosis infection 
of IFN AR-deficient (Ifnar1−/−) mice compared with WT controls 
although this phenotype has not been universally observed 
(Cooper et al., 2000; Antonelli et al., 2010; Desvignes et al., 2012; 
McNab et al., 2013; Redford et al., 2014; Moreira-Teixeira et al., 
2016, 2017). The reasons underlying the discrepancies in the 
results of these studies (summarized in Table 2) are presently 
unclear but may relate to differences in the M. tuberculosis 
strains used for challenge, host genetic background of the differ-
ent colonies of Ifnar1−/− mice used, or environmental differences.
Elevated production of type I IFN has been associated with the 
virulence of M. tuberculosis strains and increased host suscep-
tibility. Studies of infection with hypervirulent M. tuberculosis 
clinical isolates (e.g., HN878 and BTB 02–171) compared with the 
less virulent laboratory strain (H37Rv) showed a positive cor-
relation between increased levels of type I IFN and increased 
mycobacterial virulence (Manca et al., 2001, 2005; Ordway et 
al., 2007; Carmona et al., 2013). However, similar bacterial loads 
and survival were reported in Ifnar1−/− and WT controls in the 
M. tuberculosis–resistant C57BL/6 genetic background (McNab 
et al., 2013; Moreira-Teixeira et al., 2017). IFN AR deficiency in 
mice with a M. tuberculosis–susceptible genetic background 
(A129, 129S2) enhanced host survival following infection with 
not only the hypervirulent strain HN878 (Manca et al., 2005) 
but also the less virulent H37Rv strain (Dorhoi et al., 2014). A 
stronger up-regulation of type I IFN response related genes has 
recently been reported in the blood of the highly susceptible 
129S2 mouse strain compared with the resistant C57BL/6 mouse 
strain early after infection with the M. tuberculosis strain H37Rv 
(Domaszewska et al., 2017). This increased expression of type I 
IFN–inducible genes detected in 129S2 compared with C57BL/6 
mice is consistent with the results showing that the detrimen-
tal effect of type I IFN during M. tuberculosis (laboratory strain 
H37Rv) infection is more pronounced in the highly susceptible 
129S2 strain than the resistant C57BL/6 strain (Dorhoi et al., 
2014). However, a transient protective effect of type I IFN has 
also been observed during M. tuberculosis (Erdmann strain) 
infection using the 129 strain (Cooper et al., 2000). Differing 
findings may relate to the genetic variation among 129 substrains 
(Simpson et al., 1997; Festing et al., 1999) in addition to M. tuber-
culosis strain type and the host environment. Experiments in 
which Ifnar1−/− mice of either susceptible or resistant genetic 
backgrounds are studied side by side are needed to investigate 
the basis of the discrepancy across all the studies.
Robust evidence for the role of high and sustained levels of 
type I IFN in M. tuberculosis persistence and disease pathogenesis 
has been further provided by experimental models of type I IFN 
overexpression. Direct instillation of purified murine IFN-α/β 
into the lungs of M. tuberculosis–infected B6D2/F1 mice resulted 
in increased lung bacterial loads and reduced survival of infected 
mice (Manca et al., 2001). Prolonged induction of high levels of 
type I IFN by intranasal administration of the TLR3 ligand poly-
ICLC during M. tuberculosis infection impaired control of bac-
terial growth and exacerbated pulmonary immunopathology in 
WT mice, but not in Ifnar−/− mice (Antonelli et al., 2010; Mayer-
Barber et al., 2014). Host coinfection with influenza A virus, 
another well-known inducer of type I IFN, has also been shown to 
reduce host resistance to M. tuberculosis infection via the action 
of type I IFN, because this was observed in WT, but not in IFN 
AR-deficient, mice (Redford et al., 2014). Likewise, abrogation 
of negative regulators of type I IFN signaling leading to elevated 
levels of type I IFN resulted in impaired M. tuberculosis clear-
ance (McNab et al., 2013; Dauphinee et al., 2014). Specifically, 
deletion of the MAPK kinase kinase 8 (MAP3K8; also known as 
TPL2), a negative regulator of type I IFN induction downstream 
of TLR, resulted in increased bacterial loads upon M. tubercu-
losis or L. monocytogenes infection, which was not observed in 
the absence of IFN AR (McNab et al., 2013). Impaired control of 
the bacterial loads in the absence of TPL2 was correlated with 
type I IFN–dependent induction of IL-10 and suppression of IL-12 
production during infection (McNab et al., 2013). Mice carrying 
a loss-of function mutation within the ubiquitin-specific pepti-
dase 18 (Usp18) gene, which results in increased levels of type 
I IFN production and hyperactivation of type I IFN signaling 
during bacterial infection, were also shown to be more suscep-
tible to M. tuberculosis infection, showing increased bacterial 
burdens and decreased survival (Dauphinee et al., 2014). Collec-
tively, these studies performed in experimental mouse models 
of M. tuberculosis infection point to a detrimental role of high 
and sustained levels of type I IFN in exacerbating tuberculosis.
Mechanisms of type I IFN induction in  
M. tuberculosis infection
Because type I IFN has been associated with disease pathogenesis, 
identifying mechanisms regulating type I IFN induction during 
M. tuberculosis infection has been an active area of research 
(Donovan et al., 2017; Sabir et al., 2017). In vitro studies in human 
and murine cells have shown that distinct mycobacterial mole-
cules and signaling pathways may be involved in the induction of 
this family of cytokines during M. tuberculosis infection (Fig. 1). 
High levels of type I IFN are preferentially induced by virulent 
strains of M. tuberculosis (Manca et al., 2001, 2005; Novikov et 
al., 2011; Carmona et al., 2013), and this property seems to depend 
on the well-known mycobacterial virulence factor ESX-1 protein 
secretion system (Stanley et al., 2007; Manzanillo et al., 2012; 
Wassermann et al., 2015).
Recognition of mycobacterial products in the cytosol, 
such as peptidoglycan fragments, by the cytosolic sensor 
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nucleotide-binding oligomerization containing protein 2 
(NOD2) has been shown to induce type I IFN expression by 
infected murine macrophages (Leber et al., 2008; Pandey et 
al., 2009). NOD2 activates the downstream serine/threonine-
protein kinase (TBK1)–IFN regulatory factor 5 (IRF5) signaling 
pathway, leading to the production of type I IFN (Pandey et al., 
2009). Three independent studies have identified a central role 
for the cytosolic DNA sensor nucleotidyltransferase cyclic GMP-
AMP synthase (cGAS) in the detection of mycobacterial DNA 
in the host cytosol and induction of type I IFN transcription 
in macrophages (Collins et al., 2015; Wassermann et al., 2015; 
Watson et al., 2015). The sensing of DNA by cGAS leads to 
the synthesis of the second messenger cyclic di–GMP-AMP 
(cGAMP), which activates the stimulator of IFN genes (STI NG) 
and the downstream TBK1–IRF3 signaling pathway, culminating 
in the transcription of type I IFN (Manzanillo et al., 2012; 
Collins et al., 2015; Wassermann et al., 2015; Watson et al., 
2015). Mycobacterial DNA in the host cytosol can also be sensed 
by absent in melanoma 2 (AIM-2) protein, which partially 
contributes to the activation of the NLRP3-inflammasome, 
promoting the maturation of the protective cytokine IL-1β (Shah 
et al., 2013; Wassermann et al., 2015). This AIM-2–IL-1β signaling 
pathway has been recently reported to negatively regulate the 
STI NG-dependent type I IFN production in macrophages and 
dendritic cells (DCs) by inhibiting the association between STI 
NG and TBK1 (Yan et al., 2018).
Table 2. Summary of outcomes reported following aerosol infection with M. tuberculosis in Ifnar−/− mice
Mtb 
strain
Dose 
(CFU)
Mouse 
background
Bacterial loadsa Lung pathologya Survivala Reference
Lung Spleen
H37Rv 100 C57BL/6 (R) Increased (day 28 p.i.) — — — Antonelli et al., 
2010
H37Rv 100–150 C57BL/6 (R) Decreased (day 28 p.i.) — — — Mayer-Barber et al., 
2011
H37Rv 100 C57BL/6 (R) Transiently decreased (day 18 
p.i.) but similar at day 25 p.i.
— — Similar (day 70 p.i.) Desvignes et al., 
2012
H37Rv 50–150 C57BL/6 (R) Similar (day 27 p.i.) — — — Redford et al., 
2014
H37Rv 100–150 C57BL/6 (R) — — — Similar (day 80 p.i.) Mayer-Barber et al., 
2014
H37Rv 500 (200 
for survival)
C57BL/6 (R) Decreased (day 42 p.i.) — — Similar (day 80 p.i.) Dorhoi et al., 2014
200 129S2 (S) Decreased (day 21 p.i.) — Decreased (day 21 p.i.) Increased
H37Rv 50–100 KO 129 (S);  
WT C57BL/6 (R)
Decreased (chronic phase,  
> day 75 p.i.)
— — — Ordway et al., 2007
Erdman 106 (i.v.) C57BL/6 (R) Similar (days 10, 21 p.i.) Decreased (days 10, 
21 p.i.)
— — Stanley et al., 2007
Erdman 100 C57BL/6 (R) Transiently decreased (day 7 p.i.) 
but similar at days 21, 77, 100, 
245 p.i.
Transiently decreased 
at day 77 p.i. but 
similar at other time 
points
Similar (days 100, 275 p.i.) Increased Kimmey et al., 
2017
Erdman 100 B6/129 (S) Transiently increased (days 10, 
20, 40 p.i.) but similar by day 
80 p.i.
— — — Cooper et al., 2000
Erdman 50–100 KO 129 (S);  
WT C57BL/6 (R)
Decreased (> day 25 p.i.) — — Similar (day 200 p.i.) Ordway et al., 2007
CSU93 50–100 KO 129 (S);  
WT C57BL/6 (R)
Decreased (> day 25 p.i.) — — Similar (day 200 p.i.) Ordway et al., 2007
HN878 100–200 C57BL/6 (R) Similar (days 28, 60 p.i.) — — — Moreira-Teixeira et 
al., 2017
HN878 30 C57BL/6 (R) Similar (day 48 p.i.) — — — McNab et al., 2013
HN878 100–200 129 (S) — — — Increased Manca et al., 2005
HN878 50–100 KO 129 (S);  
WT C57BL/6 (R)
Decreased (> day 50 p.i.) — — Similar (day 200 p.i.) Ordway et al., 2007
BTB 
02-171
30 C57BL/6 (R) Similar (day 56 p.i.) — — — McNab et al., 2013
BTB 
02-171
100–200 C57BL/6 (R) Similar (days 20, 24, 27 p.i.) — Similar (day 27 p.i.) Similar (> day 200 p.i.) Moreira-Teixeira et 
al., 2016
Dashes indicate no data reported. Mtb, M. tuberculosis; p.i., postinfection; (R), M. tuberculosis–resistant mouse strain; (S), M. tuberculosis–susceptible 
mouse strain.
aCompared with WT mice.
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A more recent study suggested that cGAS/STI NG–dependent 
type I IFN induction in macrophages can also be triggered by 
mitochondrial DNA released into the cytosol due to mitochon-
drial stress caused by M. tuberculosis infection (Wiens and Ernst, 
2016). Production of cyclic di-AMP (c-di-AMP) by M. tubercu-
losis has also been shown to promote type I IFN induction in a 
STI NG-dependent but cGAS-independent mechanism (Dey et al., 
2015). STI NG-dependent induction of type I IFN can be regulated 
by mycobacterial and host phosphodiesterases, which inhibit STI 
NG activation and consequent induction of type I IFN by hydro-
lysis of both mycobacterial-derived c-di-AMP and host-derived 
cGAMP (Dey et al., 2017).
TLRs are another set of pattern recognition receptors (PRRs) 
that are important for sensing M. tuberculosis infection (Stamm 
et al., 2015). Whereas some M. tuberculosis strains activate 
mainly TLR2, others also activate TLR4 and the downstream 
MyD88-independent TIR domain–containing adapter-inducing 
IFN-β (TRIF), resulting in different macrophage responses char-
acterized by varying production of type I IFN (Carmona et al., 
2013; Moreira-Teixeira et al., 2016). Sensing of M. tuberculosis 
infection by C-type lectin receptors has also been reported to 
induce type I IFN production by B cells (Benard et al., 2017) and 
to amplify type I IFN responses in DCs (Troegeler et al., 2017). In 
B cells, induction of type I IFN during M. tuberculosis infection 
has also been shown to require the STI NG signaling pathway and 
to be negatively regulated by MyD88 (Benard et al., 2017).
These studies indicate that different M. tuberculosis strains 
can induce type I IFN by triggering multiple cell surface and 
cytosolic PRR and downstream signaling pathways (Fig. 1), which 
may contribute to the differential levels of type I IFN and viru-
lence induced by distinct strains. Further studies are required 
to determine the relative importance of each of these pathways 
in vivo and determine how widely they function in different cell 
types, as they could provide novel targets for tuberculosis pre-
vention and therapy.
Pathogenic effects of type I IFN signaling during  
M. tuberculosis infection
Studies performed in patients and mouse models of infection 
collectively point to a harmful role of high and sustained type I 
IFN in tuberculosis (discussed above). However, the mechanisms 
by which type I IFN signaling exacerbates M. tuberculosis infec-
tion are not yet fully understood (Mayer-Barber and Sher, 2015; 
McNab et al., 2015; Donovan et al., 2017; Sabir et al., 2017). Early 
studies with hypervirulent strains of M. tuberculosis associated 
the induction of higher levels of type I IFN with the suppression 
of proinflammatory cytokines and impaired antibacterial Th1 
responses (Manca et al., 2001, 2005; Ordway et al., 2007). The 
Figure 1. Alternative pathways of type I IFN induction during M. tuberculosis infection. Recognition of mycobacterial products by a range of cell surface 
and cytosolic PRR, including TLR4, NOD2, and STI NG, activates the kinase TBK1 leading to phosphorylation (P) and dimerization of IRF3 or IRF5, which trans-
locates into the nucleus and promotes transcription of type I IFN genes. Release of mycobacterial or mitochondrial DNA in the cytosol activates cGAS, which 
synthesizes cGAMP. Host-derived cGAMP and/or mycobacterial-derived c-di-AMP activates the STI NG pathway and the downstream TBK1–IRF3 signaling 
axis. Peptidoglycan fragments can be sensed by NOD2 in the cytosol, activating the TBK1–IRF5 signaling pathway. Detection of extracellular M. tuberculosis 
and/or its products by TLR4 triggers TRIF-TBK1-IRF3–dependent induction of type I IFN by certain strains. Mtb, M. tuberculosis; mtDNA, mitochondrial DNA; 
PGN, peptidoglycan.
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inhibition of host-protective cytokines and innate cell respon-
siveness in addition to IFN-γ–driven antibacterial effects by type 
I IFN has since been verified by several other studies both in 
human cells (Mayer-Barber et al., 2011; Novikov et al., 2011; de 
Paus et al., 2013; Teles et al., 2013) and mouse models (Mayer-
Barber et al., 2011; McNab et al., 2013, 2014; Dorhoi et al., 2014). 
In addition, type I IFN has also been shown to promote early cell 
death of alveolar macrophages (Dorhoi et al., 2014) and boost 
the local accumulation of permissive myeloid cells, which con-
tribute to the spread of infection and pulmonary inflammation 
(Antonelli et al., 2010; Dorhoi et al., 2014), underlining the com-
plex role of type I IFN during M. tuberculosis infection (Fig. 2).
Type I IFN has been reported to inhibit the production of 
IL-1α and IL-1β, which are critical for host defense against M. 
tuberculosis infection (Mayer-Barber et al., 2010, 2011), both in 
vitro in infected human (Mayer-Barber et al., 2011; Novikov et 
al., 2011; de Paus et al., 2013) and mouse myeloid cells (Mayer-
Barber et al., 2011; McNab et al., 2014) and in vivo in mouse mod-
els (Mayer-Barber et al., 2011; Dorhoi et al., 2014). Prostaglandin 
E2 (PGE2) has been shown to be a critical downstream mediator 
of IL-1–dependent host resistance, and accordingly, type I IFN has 
been shown to limit PGE2 in vitro in human and mouse cells and 
in vivo (Mayer-Barber et al., 2014). PGE2 is known to prevent 
necrosis of M. tuberculosis–infected macrophages by promoting 
apoptosis, a cell death modality that contains the pathogen, 
limiting its dissemination (Chen et al., 2008; Divangahi et al., 
2009). Thus, an additional mechanism by which type I IFN could 
enhance M. tuberculosis infection and disease is through promo-
tion of necrosis as a consequence of PGE2 inhibition.
In turn, it has recently been demonstrated that there is a 
reciprocal control of type I IFN regulation by IL-1β through a 
PGE2-mediated mechanism (Mayer-Barber et al., 2014). Increas-
ing the levels of PGE2 during M. tuberculosis infection, by direct 
administration of this prostanoid or by increasing its level 
through 5-lipoxygenase blockade with zileuton, limited type I 
IFN induction and conferred host resistance to infection in mice 
(Mayer-Barber et al., 2014). These findings suggest zileuton as a 
drug that could be used for host-directed therapy of tuberculosis 
by limiting detrimental type I IFN overproduction.
The production of other proinflammatory cytokines such as 
TNF-α and IL-12 has also been shown to be negatively affected 
by the addition of exogenous IFN-α or IFN-β to human mono-
cytes (de Paus et al., 2013) and murine macrophages (McNab et 
al., 2014) in in vitro cultures. Type I IFN has also been reported 
to induce the production of the immunosuppressive cytokine 
IL-10 in vitro in macrophages (Mayer-Barber et al., 2011; McNab 
et al., 2014) and in vivo in CD4+ T cells (Moreira-Teixeira et al., 
2017), which has been shown to increase susceptibility to M. 
Figure 2. Foe- and friendly-like effects of type I IFN during M. tuberculosis infection. Type I IFN has been reported to play both negative (red arrows) and 
positive (green arrows) functions during M. tuberculosis infection. (A) Tonic levels of autocrine type I IFN signaling prime the production of protective cytokines 
IL-12 and TNF-α. (B) However, high and sustained levels of type I IFN promote the production of IL-10 and inhibit the production of protective cytokines IL-12, 
TNF-α, IL-1α, and IL-1β. IL-10 mediates a suppressive feedback loop, contributing to the decreased production of IL-12 and TNF-α. Type I IFN also inhibits myeloid 
cell responsiveness to IFN-γ by both IL-10–dependent and independent mechanisms, suppressing IFN-γ–dependent host-protective immune responses. In 
addition, type I IFN can promote cell death in alveolar macrophages and accumulation of permissive myeloid cells at the site of infection. (C) In the absence of 
the IFN-γ receptor, type I IFN inhibits Arg1 expression directly or indirectly by increasing TNF-α levels, thus regulating macrophage activation toward a more 
protective phenotype. Type I IFN signaling can also promote the recruitment, differentiation, and/or survival of protective myeloid cells that control pathology 
at the site of infection. Arg1, arginase 1; IFNγR, IFN-γ receptor; IL-10R, IL-10 receptor; TNFR, TNF-α receptor.
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tuberculosis infection (Redford et al., 2011). In addition, the 
increased susceptibility of M. tuberculosis–infected mice given 
the double-stranded RNA homologue poly-ICLC, which led to 
enhanced type I IFN production, was shown to be dependent 
on IL-10 production (Mayer-Barber et al., 2014). The inhibitory 
effect of type I IFN on the production of IL-12 and TNF-α by M. 
tuberculosis–infected macrophages is abrogated in the absence 
of IL-10 (McNab et al., 2014). However, the inhibitory effect of 
type I IFN on IL-1β production is only slightly affected by IL-10 
deficiency (Mayer-Barber et al., 2011; McNab et al., 2014), indi-
cating that type I IFN suppresses the macrophage response to M. 
tuberculosis infection by both IL-10–dependent and –indepen-
dent mechanisms.
In addition, type I IFN has been shown to repress macro-
phage/monocyte responsiveness to the antibacterial effects of 
IFN-γ during mycobacterial infections (de Paus et al., 2013; Teles 
et al., 2013; McNab et al., 2014). In both mouse and human cells, 
type I IFN has been shown to suppress the ability of monocytes 
and macrophages to up-regulate antimycobacterial effector 
molecules and to restrict bacterial growth in response to both 
M. tuberculosis and M. leprae (Teles et al., 2013; McNab et al., 
2014). This inhibitory effect of type I IFN on the antimycobac-
terial activity of IFN-γ in human macrophages has shown to be 
mediated by IL-10 (Teles et al., 2013). However, the inhibition 
of IFN-γ–induced cytokine production by type I IFN in murine 
macrophages seems to be mediated by both IL-10–dependent and 
–independent mechanisms (McNab et al., 2014). Down-regula-
tion of IFN-γ–driven inducible nitric oxide synthase and IL-12/23 
p40 by type I IFN has also been reported in lung myeloid cells 
during M. tuberculosis infection in vivo (Mayer-Barber et al., 
2011; Mayer-Barber and Sher, 2015). Although induction of IL-10 
by type I IFN has been reported during M. tuberculosis infection 
in vivo (Moreira-Teixeira et al., 2017), it is not yet clear whether 
IL-10 is responsible for the suppressive effects of type I IFN on 
IFN-γ function in vivo.
Friendly protective functions of type I IFN in tuberculosis
Although a role for type I IFN in the pathogenesis of tuberculosis 
is strongly supported by studies in both human tuberculosis 
(Zhang et al., 2018) and studies in experimental mouse models 
of M. tuberculosis infection (Antonelli et al., 2010; McNab et al., 
2013; Dorhoi et al., 2014; Mayer-Barber et al., 2014; Redford et al., 
2014), there is also evidence that type I IFN can display protective 
functions under specific conditions. Several clinical case reports 
have described improved clinical symptoms and decreased 
bacterial burden after coadministration of IFN-α together 
with antimycobacterial chemotherapy to patients with active 
tuberculosis who were not responsive to conventional treatment 
and/or had recurrent disease (Giosué et al., 1998; Palmero et al., 
1999; Giosuè et al., 2000; Mansoori et al., 2002; Zarogoulidis 
et al., 2012). These clinical studies of IFN-α adjunct therapy 
were designed before the now numerous studies linking type I 
IFN expression with active tuberculosis, and the mechanisms 
underlying the beneficial effects of IFN-α administration in 
these patients remain unclear. Therapeutic effects of IFN-α 
have also been reported in young patients suffering from 
mycobacterial infections with complete or partial IFN-γ receptor 
(IFN GR) signaling deficiencies when administered together 
with antimycobacterial chemotherapy (Ward et al., 2007; 
Bax et al., 2013).
A protective role for type I IFN in the absence of IFN-γ 
signaling has also been proposed in mouse models of M. 
tuberculosis infection (Desvignes et al., 2012; Moreira-Teixeira 
et al., 2016), suggesting that the dominant suppressive effect 
of type I IFN on IFN-γ antimycobacterial activity may mask 
potentially protective functions of this family of cytokines 
(Fig. 2). These studies reported increased pulmonary pathology 
and early mortality following M. tuberculosis infection in mice 
deficient in both type I IFN and IFN-γ receptors (Ifngr1−/−
Ifnar1−/−) compared with single IFN GR-deficient mice (Ifngr1−/−; 
Desvignes et al., 2012; Moreira-Teixeira et al., 2016). In contrast 
to what has been reported in the immunocompetent host, 
where type I IFN signaling may promote local accumulation 
of permissive myeloid cells that contribute to the spread of 
infection and pulmonary inflammation (Antonelli et al., 2010; 
Dorhoi et al., 2014), in the absence of IFN-γ signaling, type I 
IFN may facilitate the recruitment, differentiation, and/or 
survival of myeloid cells that control pathology (Desvignes 
et al., 2012). Although no difference in the lung bacterial 
burden was observed during infection with the less virulent 
laboratory strain H37Rv (Desvignes et al., 2012), infection 
with the hypervirulent strain BTB 02–171, shown to induce 
high levels of type I IFN (Carmona et al., 2013), revealed 
the ability of type I IFN to also control bacterial replication 
(Moreira-Teixeira et al., 2016). Following infection with BTB 
02–171, increased lung bacterial loads were observed in double 
Ifngr1−/−Ifnar1−/− mice, which are deficient in both type I IFN 
and IFN-γ receptors, compared with single Ifngr1−/−mice. 
Increased control of bacterial replication in the absence of 
IFN-γ signaling correlated with suppression of alternative 
macrophage activation by type I IFN, likely by direct regulation 
of macrophage activation as well as by regulation of cytokine 
expression in the infected lungs (Moreira-Teixeira et al., 2016). 
These findings may help to explain some of the mechanisms 
underlying the beneficial effects of IFN-α treatment, at least in 
patients with compromised IFN-γ responses, and provide new 
avenues for host-directed therapies in tuberculosis.
Type I IFN has also been reported to increase host resistance 
in mouse models of infection against avirulent mycobacterial 
strains, such as Mycobacterium smegmatis (Ruangkiattikul et al., 
2017), Mycobacterium avium (Denis, 1991), and Mycobacterium 
bovis bacillus Calmette-Guérin (BCG; Kuchtey et al., 2006). In 
addition, it has been suggested that type I IFN may improve the 
immunogenicity of BCG vaccination against M. tuberculosis 
infection in mouse and guinea pig models (Bottai et al., 2015; 
Gröschel et al., 2017; Rivas-Santiago and Guerrero, 2017). 
Recombinant expression of the ESX-1 protein secretion system 
in the attenuated BCG vaccine has been shown to increase 
the protective effect of vaccination against M. tuberculosis 
infection (Bottai et al., 2015; Gröschel et al., 2017). This increased 
protection correlated with enhanced IFN-β production by 
macrophages infected with recombinant ESX-1–expressing BCG 
(Gröschel et al., 2017). However, the contribution of type I IFN 
in the protection conferred by ESX-1–expressing BCG vaccine 
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still requires investigation. In support for a role of type I IFN 
in increasing BCG vaccine efficacy, an independent study has 
shown that administration of IFN-α during BCG vaccination 
promotes the production of host-protective cytokines (e.g., IFN-
γ, TNF-α, and IL-12) and confers increased protection against M. 
tuberculosis infection over that observed with BCG alone (Rivas-
Santiago and Guerrero, 2017). These findings suggest that type 
I IFN may play a friendly protective role in the context of BCG-
induced immunity and could be targeted to improve preventive 
vaccination against tuberculosis.
In vitro experiments in human peripheral blood cells have 
shown that treatment with type I IFN can increase DC maturation 
and IL-12 production following BCG infection, which then 
promotes T cell priming and production of IFN-γ (Giacomini et 
al., 2009), and may help to explain the positive effects of type I 
IFN during vaccination. Whereas addition of IFN-β at the time of 
infection has been shown to negatively affect proinflammatory 
cytokine production via IL-10–dependent and –independent 
mechanisms (Mayer-Barber et al., 2011; McNab et al., 2014), basal 
type I IFN signaling has been shown to be required for maximal 
production of IL-12 and TNF-α by macrophages in response to 
M. tuberculosis infection (McNab et al., 2014). Indeed, Ifnar1−/− 
macrophages have been shown to produce lower levels of IL-12 
and TNF-α in response to M. tuberculosis infection compared 
with WT macrophages (McNab et al., 2014). Tonic type I IFN 
signaling has also been reported to be important for optimal 
IL-12 production by macrophages (Howes et al., 2016) and DCs 
(Gautier et al., 2005) in other contexts. Moreover, pretreatment 
of WT macrophages with IFN-β for >8 h before M. tuberculosis 
infection enhanced the production of IL-12 and TNF-α (McNab 
et al., 2014), indicating that the timing of type I IFN signaling 
may be important in determining the effects of type I IFN 
during M. tuberculosis infection. Thus, these findings suggest 
that early tonic type I IFN signaling can elicit friendly functions 
during M. tuberculosis infection by priming innate immune 
cells for the production of proinflammatory host-protective 
cytokines (Fig. 2).
Closing remarks
Members of the type I IFN family were first discovered for 
their ability to interfere with viral replication and are well 
known for their antiviral responses (Yan and Chen, 2012; 
Crouse et al., 2015). Unlike their largely protective role in viral 
infections, this family of cytokines plays a less predictable role 
in bacterial infection (Trinchieri, 2010; McNab et al., 2015; 
Stifter and Feng, 2015; Mayer-Barber and Yan, 2017). Over 
the past decade, numerous studies have uncovered a foe-like 
pathogenic role of type I IFN in tuberculosis. Patients with 
active tuberculosis have a blood transcriptional gene signature 
dominated by type I IFN–related genes that is correlated with 
disease severity and is down-regulated following successful 
treatment (Table 1). In experimental models, elevated levels of 
type I IFN are associated with the virulence of M. tuberculosis 
strains and increased host susceptibility. Several mechanisms 
underlying the pathogenic role of type I IFN in tuberculosis 
have been described, including induction of IL-10 and negative 
regulation of the IL-12/IFN-γ and IL-1β/PGE2 host-protective 
responses. However, there is also evidence that type I IFN 
may play a friendly role in certain contexts, highlighting the 
complex role of type I IFN in tuberculosis (Fig. 2). Although high 
levels of type I IFN have negative effects during the course of 
M. tuberculosis infection, tonic I IFN signaling or low levels of 
type I IFN in the context of low mycobacterial loads may in turn 
have positive effects by priming host-protective responses. This 
may explain the protective effects of IFN-α therapy together 
with anti-mycobacterial drugs in patients with active disease. 
Thus, it is likely that a balanced induction of this family of 
cytokines is required for optimal protection. Various signaling 
pathways have been described to induce type I IFN production 
in response to M. tuberculosis infection (Fig.  1). Differential 
activation of these pathways and/or high or low engagement 
of these signaling pathways during infection may contribute to 
the induction of distinct levels of type I IFN and the differential 
virulence of M. tuberculosis strains. In addition, potential 
differences in temporal and spatial induction of individual 
IFN-α subtypes and IFN-β during infection could contribute 
to variations in disease outcome and determine foe or friend 
features of the type I IFN response. A further unexplored area 
is the possible differential role of IFN AR subunits (IFN AR1 and 
IFN AR2) in determining the outcome of type I IFN signaling. 
Dominant IFN AR1 expression has been shown to favor IFN-β 
ligation and activation of the protein kinase B (also known as 
Akt) pathway over the classical JAK–STAT pathway (de Weerd et 
al., 2013). Therefore, differential expression of IFN AR subunits 
on the relevant responding cells during M. tuberculosis infection 
could be another factor regulating detrimental versus protective 
activities of type I IFN signaling during infection. Deciphering 
the mechanisms underlying the differential induction of type 
I IFN and what determines the outcome of type I IFN signaling 
during M. tuberculosis infection, from induction of IL-10 to the 
regulation of the IL-12/IFN-γ and IL-1β/PGE2 host-protective 
responses, may offer new avenues for host-directed therapies 
for tuberculosis. In addition, such research may yield important 
basic information about type I IFN induction and function that 
will enhance our broader understanding of how this major 
cytokine family impacts on disease outcomes.
Acknowledgments
We thank Akul Singhania for critically reading the manuscript. 
L. Moreira-Teixeira and A. O’Garra were supported by The 
Francis Crick Institute (FC001126), which receives its core fund-
ing from Cancer Research UK, the UK Medical Research Coun-
cil, and the Wellcome Trust. K. Mayer-Barber and A. Sher were 
supported by the Intramural Research Program of the National 
Institutes of Allergy and Infectious Diseases. 
The authors declare no competing financial interests.
Author contributions: L. Moreira-Teixeira and A. O'Garra 
designed the manuscript. L. Moreira-Teixeira developed the fig-
ures and tables and wrote and edited the manuscript. K. May-
er-Barber, A. Sher, and A. O'Garra contributed to the critical 
review of the literature and reviewed the article before final 
submission. All authors read and approved the manuscript 
prior to submission.
Moreira-Teixeira et al. 
Role of type I interferons in tuberculosis
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180325
10
Submitted: 16 February 2018
Revised: 28 March 2018
Accepted: 29 March 2018
References
Abutidze, A., N. Bolokadze, N. Chkhartishvili, L. Sharvadze, and T. Tsertsvadze. 
2016. Incidence of Tuberculosis among Hiv/Hcv Co-Infected Patients 
Receiving Hepatitis C Treatment with Pegylated Interferon and Ribavi-
rin in Georgia. Georgian Med. News. 252:10–15.
Altare, F., A. Durandy, D. Lammas, J.F. Emile, S. Lamhamedi, F. Le Deist, P. 
Drysdale, E. Jouanguy, R. Döffinger, F. Bernaudin, et al. 1998. Impair-
ment of mycobacterial immunity in human interleukin-12 receptor 
deficiency. Science. 280:1432–1435. https:// doi .org/ 10 .1126/ science .280 
.5368 .1432
Anderson, S.T., M. Kaforou, A.J. Brent, V.J. Wright, C.M. Banwell, G. Chaga-
luka, A.C. Crampin, H.M. Dockrell, N. French, M.S. Hamilton, et al. 2014. 
Diagnosis of childhood tuberculosis and host RNA expression in Africa. 
N. Engl. J. Med. 370:1712–1723. https:// doi .org/ 10 .1056/ NEJMoa1303657
Antonelli, L.R., A. Gigliotti Rothfuchs, R. Gonçalves, E. Roffê, A.W. Cheever, 
A. Bafica, A.M. Salazar, C.G. Feng, and A. Sher. 2010. Intranasal Poly-IC 
treatment exacerbates tuberculosis in mice through the pulmonary 
recruitment of a pathogen-permissive monocyte/macrophage popula-
tion. J. Clin. Invest. 120:1674–1682. https:// doi .org/ 10 .1172/ JCI40817
Banchereau, J., and V. Pascual. 2006. Type I interferon in systemic lupus ery-
thematosus and other autoimmune diseases. Immunity. 25:383–392. 
https:// doi .org/ 10 .1016/ j .immuni .2006 .08 .010
Bax, H.I., A.F. Freeman, L. Ding, A.P. Hsu, B. Marciano, E. Kristosturyan, T. 
Jancel, C. Spalding, J. Pechacek, K.N. Olivier, et al. 2013. Interferon alpha 
treatment of patients with impaired interferon gamma signaling. J. Clin. 
Immunol. 33:991–1001. https:// doi .org/ 10 .1007/ s10875 -013 -9882 -5
Belkahla, N., H. Kchir, N. Maamouri, H. Ouerghi, F.B. Hariz, S. Chouaib, H. 
Chaabouni, and N.B. Mami. 2010. [Reactivation of tuberculosis during 
dual therapy with pegylated interferon and ribavirin for chronic hep-
atitis C]. Rev. Med. Interne. 31:e1–e3. https:// doi .org/ 10 .1016/ j .revmed 
.2009 .11 .017
Benard, A., I. Sakwa, P. Schierloh, A. Colom, I. Mercier, L. Tailleux, L. Jouneau, 
P. Boudinot, T. Al-Saati, R. Lang, et al. 2017. B Cells Producing Type I 
Interferon Modulate Macrophage Polarization in Tuberculosis. Am. J. 
Respir. Crit. Care Med.
Berry, M.P., C.M. Graham, F.W. McNab, Z. Xu, S.A. Bloch, T. Oni, K.A. Wilkin-
son, R. Banchereau, J. Skinner, R.J. Wilkinson, et al. 2010. An inter-
feron-inducible neutrophil-driven blood transcriptional signature 
in human tuberculosis. Nature. 466:973–977. https:// doi .org/ 10 .1038/ 
nature09247
Blankley, S., C.M. Graham, J. Levin, J. Turner, M.P. Berry, C.I. Bloom, Z. Xu, V. 
Pascual, J. Banchereau, D. Chaussabel, et al. 2016. A 380-gene meta-sig-
nature of active tuberculosis compared with healthy controls. Eur. 
Respir. J. 47:1873–1876. https:// doi .org/ 10 .1183/ 13993003 .02121 -2015
Bloom, C.I., C.M. Graham, M.P. Berry, K.A. Wilkinson, T. Oni, F. Rozakeas, Z. 
Xu, J. Rossello-Urgell, D. Chaussabel, J. Banchereau, et al. 2012. Detect-
able changes in the blood transcriptome are present after two weeks 
of antituberculosis therapy. PLoS One. 7:e46191. https:// doi .org/ 10 .1371/ 
journal .pone .0046191
Bloom, C.I., C.M. Graham, M.P. Berry, F. Rozakeas, P.S. Redford, Y. Wang, Z. 
Xu, K.A. Wilkinson, R.J. Wilkinson, Y. Kendrick, et al. 2013. Transcrip-
tional blood signatures distinguish pulmonary tuberculosis, pulmonary 
sarcoidosis, pneumonias and lung cancers. PLoS One. 8:e70630. https:// 
doi .org/ 10 .1371/ journal .pone .0070630
Bogunovic, D., M. Byun, L.A. Durfee, A. Abhyankar, O. Sanal, D. Mansouri, 
S. Salem, I. Radovanovic, A.V. Grant, P. Adimi, et al. 2012. Mycobacte-
rial disease and impaired IFN-γ immunity in humans with inherited 
ISG15 deficiency. Science. 337:1684–1688. https:// doi .org/ 10 .1126/ science 
.1224026
Bottai, D., W. Frigui, S. Clark, E. Rayner, A. Zelmer, N. Andreu, M.I. de Jonge, 
G.J. Bancroft, A. Williams, P. Brodin, and R. Brosch. 2015. Increased pro-
tective efficacy of recombinant BCG strains expressing virulence-neu-
tral proteins of the ESX-1 secretion system. Vaccine. 33:2710–2718. 
https:// doi .org/ 10 .1016/ j .vaccine .2015 .03 .083
Cai, Y., Q. Yang, Y. Tang, M. Zhang, H. Liu, G. Zhang, Q. Deng, J. Huang, Z. 
Gao, B. Zhou, et al. 2014. Increased complement C1q level marks active 
disease in human tuberculosis. PLoS One. 9:e92340. https:// doi .org/ 10 
.1371/ journal .pone .0092340
Carmona, J., A. Cruz, L. Moreira-Teixeira, C. Sousa, J. Sousa, N.S. Osorio, A.L. 
Saraiva, S. Svenson, G. Kallenius, J. Pedrosa, et al. 2013. Mycobacterium 
tuberculosis Strains Are Differentially Recognized by TLRs with an 
Impact on the Immune Response. PLoS One. 8:e67277. https:// doi .org/ 10 
.1371/ journal .pone .0067277
Chen, M., M. Divangahi, H. Gan, D.S.J. Shin, S. Hong, D.M. Lee, C.N. Serhan, 
S.M. Behar, and H.G. Remold. 2008. Lipid mediators in innate immunity 
against tuberculosis: Opposing roles of PGE2 and LXA4 in the induc-
tion of macrophage death. J. Exp. Med. 205:2791–2801. https:// doi .org/ 
10 .1084/ jem .20080767
Cliff, J.M., J.S. Lee, N. Constantinou, J.E. Cho, T.G. Clark, K. Ronacher, E.C. King, 
P.T. Lukey, K. Duncan, P.D. Van Helden, et al. 2013. Distinct phases of 
blood gene expression pattern through tuberculosis treatment reflect 
modulation of the humoral immune response. J. Infect. Dis. 207:18–29. 
https:// doi .org/ 10 .1093/ infdis/ jis499
Collins, A.C., H. Cai, T. Li, L.H. Franco, X.D. Li, V.R. Nair, C.R. Scharn, C.E. 
Stamm, B. Levine, Z.J. Chen, and M.U. Shiloh. 2015. Cyclic GMP-AMP 
Synthase Is an Innate Immune DNA Sensor for Mycobacterium tuber-
culosis. Cell Host Microbe. 17:820–828. https:// doi .org/ 10 .1016/ j .chom 
.2015 .05 .005
Cooper, A.M. 2009. Cell-mediated immune responses in tuberculosis. Annu. 
Rev. Immunol. 27:393–422. https:// doi .org/ 10 .1146/ annurev .immunol 
.021908 .132703
Cooper, A.M., D.K. Dalton, T.A. Stewart, J.P. Griffin, D.G. Russell, and I.M. 
Orme. 1993. Disseminated tuberculosis in interferon γ gene-disrupted 
mice. J. Exp. Med. 178:2243–2247. https:// doi .org/ 10 .1084/ jem .178 .6 .2243
Cooper, A.M., A.D. Roberts, E.R. Rhoades, J.E. Callahan, D.M. Getzy, and I.M. 
Orme. 1995. The role of interleukin-12 in acquired immunity to Myco-
bacterium tuberculosis infection. Immunology. 84:423–432.
Cooper, A.M., J. Magram, J. Ferrante, and I.M. Orme. 1997. Interleukin 12 
(IL-12) is crucial to the development of protective immunity in mice 
intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 
186:39–45. https:// doi .org/ 10 .1084/ jem .186 .1 .39
Cooper, A.M., J.E. Pearl, J.V. Brooks, S. Ehlers, and I.M. Orme. 2000. Expres-
sion of the nitric oxide synthase 2 gene is not essential for early con-
trol of Mycobacterium tuberculosis in the murine lung. Infect. Immun. 
68:6879–6882. https:// doi .org/ 10 .1128/ IAI .68 .12 .6879 -6882 .2000
Crouse, J., U. Kalinke, and A. Oxenius. 2015. Regulation of antiviral T cell 
responses by type I interferons. Nat. Rev. Immunol. 15:231–242. https:// 
doi .org/ 10 .1038/ nri3806
Crow, Y.J. 2015. Type I interferonopathies: mendelian type I interferon up-reg-
ulation. Curr. Opin. Immunol. 32:7–12. https:// doi .org/ 10 .1016/ j .coi .2014 
.10 .005
Dauphinee, S.M., E. Richer, M.M. Eva, F. McIntosh, M. Paquet, D. Dangoor, 
C. Burkart, D.E. Zhang, S. Gruenheid, P. Gros, et al. 2014. Contribution 
of increased ISG15, ISGylation and deregulated type I IFN signaling 
in Usp18 mutant mice during the course of bacterial infections. Genes 
Immun. 15:282–292. https:// doi .org/ 10 .1038/ gene .2014 .17
Davidson, S., M.K. Maini, and A. Wack. 2015. Disease-promoting effects of 
type I interferons in viral, bacterial, and coinfections. J. Interferon Cyto-
kine Res. 35:252–264. https:// doi .org/ 10 .1089/ jir .2014 .0227
Decker, T., M. Müller, and S. Stockinger. 2005. The yin and yang of type I 
interferon activity in bacterial infection. Nat. Rev. Immunol. 5:675–687. 
https:// doi .org/ 10 .1038/ nri1684
de Jong, R., F. Altare, I.A. Haagen, D.G. Elferink, T. Boer, P.J. van Breda Vries-
man, P.J. Kabel, J.M. Draaisma, J.T. van Dissel, F.P. Kroon, et al. 1998. 
Severe mycobacterial and Salmonella infections in interleukin-12 recep-
tor-deficient patients. Science. 280:1435–1438. https:// doi .org/ 10 .1126/ 
science .280 .5368 .1435
Denis, M. 1991. Recombinant murine beta interferon enhances resistance 
of mice to systemic Mycobacterium avium infection. Infect. Immun. 
59:1857–1859.
de Oliveira Uehara, S.N., C.T. Emori, R.M. Perez, M.C. Mendes-Correa, A. de 
Souza Paiva Ferreira, A.C. de Castro Amaral Feldner, A.E. Silva, R.J. Filho, 
I.S. de Souza E Silva, and M.L. Ferraz. 2016. High incidence of tuberculo-
sis in patients treated for hepatitis C chronic infection. Braz. J. Infect. Dis. 
20:205–209. https:// doi .org/ 10 .1016/ j .bjid .2015 .12 .003
de Paus, R.A., A. van Wengen, I. Schmidt, M. Visser, E.M. Verdegaal, J.T. 
van Dissel, and E. van de Vosse. 2013. Inhibition of the type I immune 
responses of human monocytes by IFN-α and IFN-β. Cytokine. 61:645–
655. https:// doi .org/ 10 .1016/ j .cyto .2012 .12 .005
Moreira-Teixeira et al. 
Role of type I interferons in tuberculosis
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180325
11
Desvignes, L., A.J. Wolf, and J.D. Ernst. 2012. Dynamic roles of type I and type 
II IFNs in early infection with Mycobacterium tuberculosis. J. Immunol. 
188:6205–6215. https:// doi .org/ 10 .4049/ jimmunol .1200255
de Weerd, N.A., J.P. Vivian, T.K. Nguyen, N.E. Mangan, J.A. Gould, S.J. Braniff, 
L. Zaker-Tabrizi, K.Y. Fung, S.C. Forster, T. Beddoe, et al. 2013. Structural 
basis of a unique interferon-β signaling axis mediated via the receptor 
IFN AR1. Nat. Immunol. 14:901–907. https:// doi .org/ 10 .1038/ ni .2667
Dey, B., R.J. Dey, L.S. Cheung, S. Pokkali, H. Guo, J.H. Lee, and W.R. Bishai. 
2015. A bacterial cyclic dinucleotide activates the cytosolic surveillance 
pathway and mediates innate resistance to tuberculosis. Nat. Med. 
21:401–406. https:// doi .org/ 10 .1038/ nm .3813
Dey, R.J., B. Dey, Y. Zheng, L.S. Cheung, J. Zhou, D. Sayre, P. Kumar, H. Guo, 
G. Lamichhane, H.O. Sintim, and W.R. Bishai. 2017. Inhibition of innate 
immune cytosolic surveillance by an M. tuberculosis phosphodiester-
ase. Nat. Chem. Biol. 13:210–217. https:// doi .org/ 10 .1038/ nchembio .2254
Divangahi, M., M. Chen, H. Gan, D. Desjardins, T.T. Hickman, D.M. Lee, S. For-
tune, S.M. Behar, and H.G. Remold. 2009. Mycobacterium tuberculosis 
evades macrophage defenses by inhibiting plasma membrane repair. 
Nat. Immunol. 10:899–906. https:// doi .org/ 10 .1038/ ni .1758
Domaszewska, T., L. Scheuermann, K. Hahnke, H. Mollenkopf, A. Dorhoi, 
S.H.E. Kaufmann, and J. Weiner. 2017. Concordant and discordant gene 
expression patterns in mouse strains identify best-fit animal model for 
human tuberculosis. Sci. Rep. 7:12094. https:// doi .org/ 10 .1038/ s41598 
-017 -11812 -x
Donovan, M.L., T.E. Schultz, T.J. Duke, and A. Blumenthal. 2017. Type I Inter-
ferons in the Pathogenesis of Tuberculosis: Molecular Drivers and 
Immunological Consequences. Front. Immunol. 8:1633. https:// doi .org/ 
10 .3389/ fimmu .2017 .01633
Dorhoi, A., V. Yeremeev, G. Nouailles, J. Weiner III, S. Jörg, E. Heinemann, D. 
Oberbeck-Müller, J.K. Knaul, A. Vogelzang, S.T. Reece, et al. 2014. Type 
I IFN signaling triggers immunopathology in tuberculosis-susceptible 
mice by modulating lung phagocyte dynamics. Eur. J. Immunol. 44:2380–
2393. https:// doi .org/ 10 .1002/ eji .201344219
Esmail, H., R.P. Lai, M. Lesosky, K.A. Wilkinson, C.M. Graham, S. Horswell, 
A.K. Coussens, C.E. Barry III, A. O’Garra, and R.J. Wilkinson. 2018. 
Complement pathway gene activation and rising circulating immune 
complexes characterize early disease in HIV-associated tuberculosis. 
Proc. Natl. Acad. Sci. USA. 115:E964–E973. https:// doi .org/ 10 .1073/ pnas 
.1711853115
Farah, R., and J. Awad. 2007. The association of interferon with the develop-
ment of pulmonary tuberculosis. Int. J. Clin. Pharmacol. Ther. 45:598–
600. https:// doi .org/ 10 .5414/ CPP45598
Festing, M.F., E.M. Simpson, M.T. Davisson, and L.E. Mobraaten. 1999. Revised 
nomenclature for strain 129 mice. Mamm. Genome. 10:836. https:// doi 
.org/ 10 .1007/ s003359901099
Flynn, J.L., and J. Chan. 2001. Immunology of tuberculosis. Annu. Rev. Immu-
nol. 19:93–129. https:// doi .org/ 10 .1146/ annurev .immunol .19 .1 .93
Flynn, J.L., J. Chan, K.J. Triebold, D.K. Dalton, T.A. Stewart, and B.R. Bloom. 
1993. An essential role for interferon gamma in resistance to Mycobacte-
rium tuberculosis infection. J. Exp. Med. 178:2249–2254. https:// doi .org/ 
10 .1084/ jem .178 .6 .2249
Flynn, J.L., M.M. Goldstein, J. Chan, K.J. Triebold, K. Pfeffer, C.J. Lowenstein, 
R. Schreiber, T.W. Mak, and B.R. Bloom. 1995a. Tumor necrosis factor-al-
pha is required in the protective immune response against Mycobacte-
rium tuberculosis in mice. Immunity. 2:561–572. https:// doi .org/ 10 .1016/ 
1074 -7613(95)90001 -2
Flynn, J.L., M.M. Goldstein, K.J. Triebold, J. Sypek, S. Wolf, and B.R. Bloom. 
1995b. IL-12 increases resistance of BALB/c mice to Mycobacterium 
tuberculosis infection. J. Immunol. 155:2515–2524.
Fortin, A., L. Abel, J.L. Casanova, and P. Gros. 2007. Host genetics of mycobac-
terial diseases in mice and men: forward genetic studies of BCG-osis and 
tuberculosis. Annu. Rev. Genomics Hum. Genet. 8:163–192. https:// doi .org/ 
10 .1146/ annurev .genom .8 .080706 .092315
Gautier, G., M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, E.E. Bates, G. 
Trinchieri, C. Caux, and P. Garrone. 2005. A type I interferon auto-
crine-paracrine loop is involved in Toll-like receptor-induced inter-
leukin-12p70 secretion by dendritic cells. J. Exp. Med. 201:1435–1446. 
https:// doi .org/ 10 .1084/ jem .20041964
Getahun, H., A. Matteelli, R.E. Chaisson, and M. Raviglione. 2015. Latent 
Mycobacterium tuberculosis infection. N. Engl. J. Med. 372:2127–2135. 
https:// doi .org/ 10 .1056/ NEJMra1405427
Giacomini, E., M.E. Remoli, V. Gafa, M. Pardini, L. Fattorini, and E.M. Coccia. 
2009. IFN-beta improves BCG immunogenicity by acting on DC matu-
ration. J. Leukoc. Biol. 85:462–468. https:// doi .org/ 10 .1189/ jlb .0908583
Gideon, H.P., J.A. Skinner, N. Baldwin, J.L. Flynn, and P.L. Lin. 2016. Early 
Whole Blood Transcriptional Signatures Are Associated with Severity 
of Lung Inflammation in Cynomolgus Macaques with Mycobacterium 
tuberculosis Infection. J. Immunol. 197:4817–4828. https:// doi .org/ 10 
.4049/ jimmunol .1601138
Giosué, S., M. Casarini, L. Alemanno, G. Galluccio, P. Mattia, G. Pedicelli, L. 
Rebek, A. Bisetti, and F. Ameglio. 1998. Effects of aerosolized interfer-
on-alpha in patients with pulmonary tuberculosis. Am. J. Respir. Crit. 
Care Med. 158:1156–1162. https:// doi .org/ 10 .1164/ ajrccm .158 .4 .9803065
Giosuè, S., M. Casarini, F. Ameglio, P. Zangrilli, M. Palla, A.M. Altieri, and 
A. Bisetti. 2000. Aerosolized interferon-alpha treatment in patients 
with multi-drug-resistant pulmonary tuberculosis. Eur. Cytokine Netw. 
11:99–104.
Gröschel, M.I., F. Sayes, S.J. Shin, W. Frigui, A. Pawlik, M. Orgeur, R. Canetti, 
N. Honoré, R. Simeone, T.S. van der Werf, et al. 2017. Recombinant BCG 
Expressing ESX-1 of Mycobacterium marinum Combines Low Viru-
lence with Cytosolic Immune Signaling and Improved TB Protection. 
Cell Reports. 18:2752–2765. https:// doi .org/ 10 .1016/ j .celrep .2017 .02 .057
Guardigni, V., G. Fabbri, A. Grilli, and C. Contini. 2012. Successful antiviral 
treatment of chronic hepatitis C in patients with rare comorbidities. 
Two case-reports. Ann. Hepatol. 11:404–408.
Hall, J.C., and A. Rosen. 2010. Type I interferons: crucial participants in 
disease amplification in autoimmunity. Nat. Rev. Rheumatol. 6:40–49. 
https:// doi .org/ 10 .1038/ nrrheum .2009 .237
Howes, A., C. Taubert, S. Blankley, N. Spink, X. Wu, C.M. Graham, J. Zhao, 
M. Saraiva, P. Ricciardi-Castagnoli, G.J. Bancroft, and A. O’Garra. 2016. 
Differential Production of Type I IFN Determines the Reciprocal Levels 
of IL-10 and Proinflammatory Cytokines Produced by C57BL/6 and BAL-
B/c Macrophages. J. Immunol. 197:2838–2853. https:// doi .org/ 10 .4049/ 
jimmunol .1501923
Ivashkiv, L.B., and L.T. Donlin. 2014. Regulation of type I interferon responses. 
Nat. Rev. Immunol. 14:36–49. https:// doi .org/ 10 .1038/ nri3581
Jacobsen, M., D. Repsilber, A. Gutschmidt, A. Neher, K. Feldmann, H.J. Mol-
lenkopf, A. Ziegler, and S.H. Kaufmann. 2007. Candidate biomarkers 
for discrimination between infection and disease caused by Mycobac-
terium tuberculosis. J. Mol. Med. (Berl.). 85:613–621. https:// doi .org/ 10 
.1007/ s00109 -007 -0157 -6
Joosten, S.A., H.A. Fletcher, and T.H. Ottenhoff. 2013. A helicopter perspective 
on TB biomarkers: pathway and process based analysis of gene expres-
sion data provides new insight into TB pathogenesis. PLoS One. 8:e73230. 
https:// doi .org/ 10 .1371/ journal .pone .0073230
Jouanguy, E., S. Lamhamedi-Cherradi, D. Lammas, S.E. Dorman, M.C. Fon-
danèche, S. Dupuis, R. Döffinger, F. Altare, J. Girdlestone, J.F. Emile, et al. 
1999. A human IFN GR1 small deletion hotspot associated with dominant 
susceptibility to mycobacterial infection. Nat. Genet. 21:370–378. https:// 
doi .org/ 10 .1038/ 7701
Kaforou, M., V.J. Wright, T. Oni, N. French, S.T. Anderson, N. Bangani, C.M. 
Banwell, A.J. Brent, A.C. Crampin, H.M. Dockrell, et al. 2013. Detection 
of tuberculosis in HIV-infected and -uninfected African adults using 
whole blood RNA expression signatures: a case-control study. PLoS Med. 
10:e1001538. https:// doi .org/ 10 .1371/ journal .pmed .1001538
Keane, J., S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwiet-
erman, J.N. Siegel, and M.M. Braun. 2001. Tuberculosis associated with 
infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. 
Med. 345:1098–1104. https:// doi .org/ 10 .1056/ NEJMoa011110
Kimmey, J.M., J.A. Campbell, L.A. Weiss, K.J. Monte, D.J. Lenschow, and C.L. 
Stallings. 2017. The impact of ISGylation during Mycobacterium tuber-
culosis infection in mice. Microbes Infect. 19:249–258. https:// doi .org/ 10 
.1016/ j .micinf .2016 .12 .006
Kuchtey, J., S.A. Fulton, S.M. Reba, C.V. Harding, and W.H. Boom. 2006. Inter-
feron-alphabeta mediates partial control of early pulmonary Mycobac-
terium bovis bacillus Calmette-Guérin infection. Immunology. 118:39–49. 
https:// doi .org/ 10 .1111/ j .1365 -2567 .2006 .02337 .x
Lawn, S.D., and A.I. Zumla. 2011. Tuberculosis. Lancet. 378:57–72. https:// doi 
.org/ 10 .1016/ S0140 -6736(10)62173 -3
Leber, J.H., G.T. Crimmins, S. Raghavan, N.P. Meyer-Morse, J.S. Cox, and 
D.A. Portnoy. 2008. Distinct TLR- and NLR-mediated transcriptional 
responses to an intracellular pathogen. PLoS Pathog. 4:e6. https:// doi 
.org/ 10 .1371/ journal .ppat .0040006
Maertzdorf, J., M. Ota, D. Repsilber, H.J. Mollenkopf, J. Weiner, P.C. Hill, and 
S.H. Kaufmann. 2011a. Functional correlations of pathogenesis-driven 
gene expression signatures in tuberculosis. PLoS One. 6:e26938. https:// 
doi .org/ 10 .1371/ journal .pone .0026938
Moreira-Teixeira et al. 
Role of type I interferons in tuberculosis
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180325
12
Maertzdorf, J., D. Repsilber, S.K. Parida, K. Stanley, T. Roberts, G. Black, G. 
Walzl, and S.H. Kaufmann. 2011b. Human gene expression profiles of 
susceptibility and resistance in tuberculosis. Genes Immun. 12:15–22. 
https:// doi .org/ 10 .1038/ gene .2010 .51
Maertzdorf, J., J. Weiner III, H.J. Mollenkopf, T. Bauer, A. Prasse, J. 
Müller-Quernheim, S.H. Kaufmann, and S.H. Kaufmann. TBornotTB 
Network. 2012. Common patterns and disease-related signatures in 
tuberculosis and sarcoidosis. Proc. Natl. Acad. Sci. USA. 109:7853–7858. 
https:// doi .org/ 10 .1073/ pnas .1121072109
Manca, C., L. Tsenova, A. Bergtold, S. Freeman, M. Tovey, J.M. Musser, C.E. 
Barry III, V.H. Freedman, and G. Kaplan. 2001. Virulence of a Mycobac-
terium tuberculosis clinical isolate in mice is determined by failure to 
induce Th1 type immunity and is associated with induction of IFN-alpha 
/beta. Proc. Natl. Acad. Sci. USA. 98:5752–5757. https:// doi .org/ 10 .1073/ 
pnas .091096998
Manca, C., L. Tsenova, S. Freeman, A.K. Barczak, M. Tovey, P.J. Murray, C. 
Barry, and G. Kaplan. 2005. Hypervirulent M. tuberculosis W/Beijing 
strains upregulate type I IFNs and increase expression of negative reg-
ulators of the Jak-Stat pathway. J. Interferon Cytokine Res. 25:694–701. 
https:// doi .org/ 10 .1089/ jir .2005 .25 .694
Mansoori, D., S. Tavana, M. Mirsaeidi, M. Yazdanpanah, and H. Sohrabpour. 
2002. The efficacy of interferon-α in the treatment of multidrug resis-
tant tuberculosis. Tanaffos. 1:29–34.
Manzanillo, P.S., M.U. Shiloh, D.A. Portnoy, and J.S. Cox. 2012. Mycobacterium 
tuberculosis activates the DNA-dependent cytosolic surveillance path-
way within macrophages. Cell Host Microbe. 11:469–480. https:// doi .org/ 
10 .1016/ j .chom .2012 .03 .007
Matsuoka, S., H. Fujikawa, H. Hasegawa, T. Ochiai, Y. Watanabe, and M. Mori-
yama. 2016. Onset of Tuberculosis from a Pulmonary Latent Tubercu-
losis Infection during Antiviral Triple Therapy for Chronic Hepatitis C. 
Intern. Med. 55:2011–2017. https:// doi .org/ 10 .2169/ internalmedicine .55 
.6448
Mayer-Barber, K.D., and A. Sher. 2015. Cytokine and lipid mediator networks 
in tuberculosis. Immunol. Rev. 264:264–275. https:// doi .org/ 10 .1111/ imr 
.12249
Mayer-Barber, K.D., and B. Yan. 2017. Clash of the Cytokine Titans: count-
er-regulation of interleukin-1 and type I interferon-mediated inflam-
matory responses. Cell. Mol. Immunol. 14:22–35. https:// doi .org/ 10 .1038/ 
cmi .2016 .25
Mayer-Barber, K.D., D.L. Barber, K. Shenderov, S.D. White, M.S. Wilson, A. 
Cheever, D. Kugler, S. Hieny, P. Caspar, G. Núñez, et al. 2010. Caspase-1 
independent IL-1beta production is critical for host resistance to myco-
bacterium tuberculosis and does not require TLR signaling in vivo. J. 
Immunol. 184:3326–3330. https:// doi .org/ 10 .4049/ jimmunol .0904189
Mayer-Barber, K.D., B.B. Andrade, D.L. Barber, S. Hieny, C.G. Feng, P. Caspar, 
S. Oland, S. Gordon, and A. Sher. 2011. Innate and adaptive interferons 
suppress IL-1α and IL-1β production by distinct pulmonary myeloid sub-
sets during Mycobacterium tuberculosis infection. Immunity. 35:1023–
1034. https:// doi .org/ 10 .1016/ j .immuni .2011 .12 .002
Mayer-Barber, K.D., B.B. Andrade, S.D. Oland, E.P. Amaral, D.L. Barber, J. Gon-
zales, S.C. Derrick, R. Shi, N.P. Kumar, W. Wei, et al. 2014. Host-directed 
therapy of tuberculosis based on interleukin-1 and type I interferon 
crosstalk. Nature. 511:99–103. https:// doi .org/ 10 .1038/ nature13489
McNab, F.W., J. Ewbank, R. Rajsbaum, E. Stavropoulos, A. Martirosyan, P.S. 
Redford, X. Wu, C.M. Graham, M. Saraiva, P. Tsichlis, et al. 2013. TPL-2-
ERK1/2 signaling promotes host resistance against intracellular bacte-
rial infection by negative regulation of type I IFN production. J. Immunol. 
191:1732–1743. https:// doi .org/ 10 .4049/ jimmunol .1300146
McNab, F.W., J. Ewbank, A. Howes, L. Moreira-Teixeira, A. Martirosyan, N. 
Ghilardi, M. Saraiva, and A. O’Garra. 2014. Type I IFN induces IL-10 pro-
duction in an IL-27-independent manner and blocks responsiveness to 
IFN-γ for production of IL-12 and bacterial killing in Mycobacterium 
tuberculosis-infected macrophages. J. Immunol. 193:3600–3612. https:// 
doi .org/ 10 .4049/ jimmunol .1401088
McNab, F., K. Mayer-Barber, A. Sher, A. Wack, and A. O’Garra. 2015. Type I 
interferons in infectious disease. Nat. Rev. Immunol. 15:87–103. https:// 
doi .org/ 10 .1038/ nri3787
Mistry, R., J.M. Cliff, C.L. Clayton, N. Beyers, Y.S. Mohamed, P.A. Wilson, H.M. 
Dockrell, D.M. Wallace, P.D. van Helden, K. Duncan, and P.T. Lukey. 2007. 
Gene-expression patterns in whole blood identify subjects at risk for 
recurrent tuberculosis. J. Infect. Dis. 195:357–365. https:// doi .org/ 10 
.1086/ 510397
Moreira-Teixeira, L., J. Sousa, F.W. McNab, E. Torrado, F. Cardoso, H. Machado, 
F. Castro, V. Cardoso, J. Gaifem, X. Wu, et al. 2016. Type I IFN Inhibits 
Alternative Macrophage Activation during Mycobacterium tuberculo-
sis Infection and Leads to Enhanced Protection in the Absence of IFN-γ 
Signaling. J. Immunol. 197:4714–4726. https:// doi .org/ 10 .4049/ jimmunol 
.1600584
Moreira-Teixeira, L., P.S. Redford, E. Stavropoulos, N. Ghilardi, C.L. Maynard, 
C.T. Weaver, A.P. Freitas do Rosário, X. Wu, J. Langhorne, and A. O’Garra. 
2017. T Cell-Derived IL-10 Impairs Host Resistance toMycobacterium 
tuberculosisInfection. J. Immunol. 199:613–623. https:// doi .org/ 10 .4049/ 
jimmunol .1601340
Newport, M.J., C.M. Huxley, S. Huston, C.M. Hawrylowicz, B.A. Oostra, R. Wil-
liamson, and M. Levin. 1996. A mutation in the interferon-gamma-re-
ceptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 
335:1941–1949. https:// doi .org/ 10 .1056/ NEJM199612263352602
North, R.J., and Y.J. Jung. 2004. Immunity to tuberculosis. Annu. Rev. Immu-
nol. 22:599–623. https:// doi .org/ 10 .1146/ annurev .immunol .22 .012703 
.104635
Novikov, A., M. Cardone, R. Thompson, K. Shenderov, K.D. Kirschman, K.D. 
Mayer-Barber, T.G. Myers, R.L. Rabin, G. Trinchieri, A. Sher, and C.G. 
Feng. 2011. Mycobacterium tuberculosis triggers host type I IFN sig-
naling to regulate IL-1β production in human macrophages. J. Immunol. 
187:2540–2547. https:// doi .org/ 10 .4049/ jimmunol .1100926
O’Garra, A., P.S. Redford, F.W. McNab, C.I. Bloom, R.J. Wilkinson, and M.P. 
Berry. 2013. The immune response in tuberculosis. Annu. Rev. Immunol. 
31:475–527. https:// doi .org/ 10 .1146/ annurev -immunol -032712 -095939
Ordway, D., M. Henao-Tamayo, M. Harton, G. Palanisamy, J. Troudt, C. Shan-
ley, R.J. Basaraba, and I.M. Orme. 2007. The hypervirulent Mycobacte-
rium tuberculosis strain HN878 induces a potent TH1 response followed 
by rapid down-regulation. J. Immunol. 179:522–531. https:// doi .org/ 10 
.4049/ jimmunol .179 .1 .522
Ottenhoff, T.H., R.H. Dass, N. Yang, M.M. Zhang, H.E. Wong, E. Sahiratm-
adja, C.C. Khor, B. Alisjahbana, R. van Crevel, S. Marzuki, et al. 2012. 
Genome-wide expression profiling identifies type 1 interferon response 
pathways in active tuberculosis. PLoS One. 7:e45839. https:// doi .org/ 10 
.1371/ journal .pone .0045839
Palmero, D., K. Eiguchi, P. Rendo, L. Castro Zorrilla, E. Abbate, and L.J. González 
Montaner. 1999. Phase II trial of recombinant interferon-alpha2b in 
patients with advanced intractable multidrug-resistant pulmonary 
tuberculosis: long-term follow-up. Int. J. Tuberc. Lung Dis. 3:214–218.
Pandey, A.K., Y. Yang, Z. Jiang, S.M. Fortune, F. Coulombe, M.A. Behr, K.A. 
Fitzgerald, C.M. Sassetti, and M.A. Kelliher. 2009. NOD2, RIP2 and IRF5 
play a critical role in the type I interferon response to Mycobacterium 
tuberculosis. PLoS Pathog. 5:e1000500. https:// doi .org/ 10 .1371/ journal 
.ppat .1000500
Pestka, S., C.D. Krause, and M.R. Walter. 2004. Interferons, interferon-like 
cytokines, and their receptors. Immunol. Rev. 202:8–32. https:// doi .org/ 
10 .1111/ j .0105 -2896 .2004 .00204 .x
Post, F.A., R. Wood, and G.P. Pillay. 1995. Pulmonary tuberculosis in HIV 
infection: radiographic appearance is related to CD4+ T-lympho-
cyte count. Tuber. Lung Dis. 76:518–521. https:// doi .org/ 10 .1016/ 0962 
-8479(95)90527 -8
Redford, P.S., P.J. Murray, and A. O’Garra. 2011. The role of IL-10 in immune 
regulation during M. tuberculosis infection. Mucosal Immunol. 4:261–
270. https:// doi .org/ 10 .1038/ mi .2011 .7
Redford, P.S., K.D. Mayer-Barber, F.W. McNab, E. Stavropoulos, A. Wack, A. 
Sher, and A. O’Garra. 2014. Influenza A virus impairs control of Myco-
bacterium tuberculosis coinfection through a type I interferon recep-
tor-dependent pathway. J. Infect. Dis. 209:270–274. https:// doi .org/ 10 
.1093/ infdis/ jit424
Rivas-Santiago, C.E., and G.G. Guerrero. 2017. IFN-αBoosting of Mycobacte-
rium bovis Bacillus Calmette Güerin-Vaccine Promoted Th1 Type Cellu-
lar Response and Protection against M. tuberculosis Infection. BioMed 
Res. Int. 2017:8796760. https:// doi .org/ 10 .1155/ 2017/ 8796760
Roe, J.K., N. Thomas, E. Gil, K. Best, E. Tsaliki, S. Morris-Jones, S. Stafford, N. 
Simpson, K.D. Witt, B. Chain, et al. 2016. Blood transcriptomic diagnosis 
of pulmonary and extrapulmonary tuberculosis. JCI Insight. 1:e87238. 
https:// doi .org/ 10 .1172/ jci .insight .87238
Ruangkiattikul, N., A. Nerlich, K. Abdissa, S. Lienenklaus, A. Suwandi, N. 
Janze, K. Laarmann, J. Spanier, U. Kalinke, S. Weiss, and R. Goethe. 2017. 
cGAS-STI NG-TBK1-IRF3/7 induced interferon-β contributes to the 
clearing of non tuberculous mycobacterial infection in mice. Virulence. 
8:1303–1315. https:// doi .org/ 10 .1080/ 21505594 .2017 .1321191
Sabbatani, S., R. Manfredi, G. Marinacci, M. Pavoni, L. Cristoni, and F. Chi-
odo. 2006. Reactivation of severe, acute pulmonary tuberculosis during 
treatment with pegylated interferon-alpha and ribavirin for chronic 
Moreira-Teixeira et al. 
Role of type I interferons in tuberculosis
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20180325
13
HCV hepatitis. Scand. J. Infect. Dis. 38:205–208. https:// doi .org/ 10 .1080/ 
00365540500263268
Sabir, N., T. Hussain, S.Z.A. Shah, D. Zhao, and X. Zhou. 2017. IFN-β: A Con-
tentious Player in Host-Pathogen Interaction in Tuberculosis. Int. J. Mol. 
Sci. 18:2725. https:// doi .org/ 10 .3390/ ijms18122725
Sambarey, A., A. Devaprasad, P. Baloni, M. Mishra, A. Mohan, P. Tyagi, A. Singh, 
J.S. Akshata, R. Sultana, S. Buggi, and N. Chandra. 2017a. Meta-analysis 
of host response networks identifies a common core in tuberculosis. NPJ 
Syst. Biol. Appl. 3:4. https:// doi .org/ 10 .1038/ s41540 -017 -0005 -4
Sambarey, A., A. Devaprasad, A. Mohan, A. Ahmed, S. Nayak, S. Swaminathan, 
G. D’Souza, A. Jesuraj, C. Dhar, S. Babu, et al. 2017b. Unbiased Identi-
fication of Blood-based Biomarkers for Pulmonary Tuberculosis by 
Modeling and Mining Molecular Interaction Networks. EBioMedicine. 
15:112–126. https:// doi .org/ 10 .1016/ j .ebiom .2016 .12 .009
Scriba, T.J., A. Penn-Nicholson, S. Shankar, T. Hraha, E.G. Thompson, D. Ster-
ling, E. Nemes, F. Darboe, S. Suliman, L.M. Amon, et al. other members 
of the ACS cohort study team. 2017. Sequential inflammatory processes 
define human progression from M. tuberculosis infection to tubercu-
losis disease. PLoS Pathog. 13:e1006687. https:// doi .org/ 10 .1371/ journal 
.ppat .1006687
Shah, S., A. Bohsali, S.E. Ahlbrand, L. Srinivasan, V.A.K. Rathinam, S.N. Vogel, 
K.A. Fitzgerald, F.S. Sutterwala, and V. Briken. 2013. Cutting edge: Myco-
bacterium tuberculosis but not nonvirulent mycobacteria inhibits IFN-β 
and AIM2 inflammasome-dependent IL-1β production via its ESX-1 
secretion system. J. Immunol. 191:3514–3518. https:// doi .org/ 10 .4049/ 
jimmunol .1301331
Simpson, E.M., C.C. Linder, E.E. Sargent, M.T. Davisson, L.E. Mobraaten, and 
J.J. Sharp. 1997. Genetic variation among 129 substrains and its impor-
tance for targeted mutagenesis in mice. Nat. Genet. 16:19–27. https:// doi 
.org/ 10 .1038/ ng0597 -19
Singhania, A., R. Verma, C.M. Graham, J. Lee, T. Trang, M. Richarsdon, P. 
Lecine, P. Leissner, M.P.R. Berry, R.J. Wilkinson, et al. 2017. A modular 
transcriptional signature identifies phenotypic heterogeneity of human 
tuberculosis infection. bioRxiv. https:// doi .org/ 10 .1101/ 216879
Stamm, C.E., A.C. Collins, and M.U. Shiloh. 2015. Sensing of Mycobacterium 
tuberculosis and consequences to both host and bacillus. Immunol. Rev. 
264:204–219. https:// doi .org/ 10 .1111/ imr .12263
Stanley, S.A., J.E. Johndrow, P. Manzanillo, and J.S. Cox. 2007. The Type I 
IFN response to infection with Mycobacterium tuberculosis requires 
ESX-1-mediated secretion and contributes to pathogenesis. J. Immunol. 
178:3143–3152. https:// doi .org/ 10 .4049/ jimmunol .178 .5 .3143
Stifter, S.A., and C.G. Feng. 2015. Interfering with immunity: detrimental role 
of type I IFNs during infection. J. Immunol. 194:2455–2465. https:// doi 
.org/ 10 .4049/ jimmunol .1402794
Teles, R.M., T.G. Graeber, S.R. Krutzik, D. Montoya, M. Schenk, D.J. Lee, E. 
Komisopoulou, K. Kelly-Scumpia, R. Chun, S.S. Iyer, et al. 2013. Type 
I interferon suppresses type II interferon-triggered human anti-my-
cobacterial responses. Science. 339:1448–1453. https:// doi .org/ 10 .1126/ 
science .1233665
Telesca, C., M. Angelico, P. Piccolo, L. Nosotti, A. Morrone, C. Longhi, M. Car-
bone, and L. Baiocchi. 2007. Interferon-alpha treatment of hepatitis D 
induces tuberculosis exacerbation in an immigrant. J. Infect. 54:e223–
e226. https:// doi .org/ 10 .1016/ j .jinf .2006 .12 .009
Trinchieri, G. 2010. Type I interferon: Friend or foe? J. Exp. Med. 207:2053–
2063. https:// doi .org/ 10 .1084/ jem .20101664
Troegeler, A., I. Mercier, C. Cougoule, D. Pietretti, A. Colom, C. Duval, T.P. Vu 
Manh, F. Capilla, R. Poincloux, K. Pingris, et al. 2017. C-type lectin recep-
tor DCIR modulates immunity to tuberculosis by sustaining type I inter-
feron signaling in dendritic cells. Proc. Natl. Acad. Sci. USA. 114:E540–
E549. https:// doi .org/ 10 .1073/ pnas .1613254114
Ward, C.M., H. Jyonouchi, S.V. Kotenko, S.V. Smirnov, R. Patel, H. Aguila, G. 
McSherry, B. Dashefsky, and S.M. Holland. 2007. Adjunctive treatment 
of disseminated Mycobacterium avium complex infection with inter-
feron alpha-2b in a patient with complete interferon-gamma receptor 
R1 deficiency. Eur. J. Pediatr. 166:981–985. https:// doi .org/ 10 .1007/ s00431 
-006 -0339 -1
Wassermann, R., M.F. Gulen, C. Sala, S.G. Perin, Y. Lou, J. Rybniker, J.L. 
Schmid-Burgk, T. Schmidt, V. Hornung, S.T. Cole, and A. Ablasser. 2015. 
Mycobacterium tuberculosis Differentially Activates cGAS- and Inflam-
masome-Dependent Intracellular Immune Responses through ESX-1. 
Cell Host Microbe. 17:799–810. https:// doi .org/ 10 .1016/ j .chom .2015 .05 
.003
Watson, R.O., S.L. Bell, D.A. MacDuff, J.M. Kimmey, E.J. Diner, J. Olivas, R.E. 
Vance, C.L. Stallings, H.W. Virgin, and J.S. Cox. 2015. The Cytosolic 
Sensor cGAS Detects Mycobacterium tuberculosis DNA to Induce Type 
I Interferons and Activate Autophagy. Cell Host Microbe. 17:811–819. 
https:// doi .org/ 10 .1016/ j .chom .2015 .05 .004
Wiens, K.E., and J.D. Ernst. 2016. The Mechanism for Type I Interferon Induc-
tion by Mycobacterium tuberculosis is Bacterial Strain-Dependent. PLoS 
Pathog. 12:e1005809. https:// doi .org/ 10 .1371/ journal .ppat .1005809
World Health Organization. 2017. Global Tuberculosis Report 2017. World 
Health Organization, Geneva. 262 pp.
Yan, N., and Z.J. Chen. 2012. Intrinsic antiviral immunity. Nat. Immunol. 
13:214–222. https:// doi .org/ 10 .1038/ ni .2229
Yan, S., H. Shen, Q. Lian, W. Jin, R. Zhang, X. Lin, W. Gu, X. Sun, G. Meng, Z. 
Tian, et al. 2018. Deficiency of the AIM2-ASC Signal Uncovers the STI 
NG-Driven Overreactive Response of Type I IFN and Reciprocal Depres-
sion of Protective IFN-γ Immunity in Mycobacterial Infection. J. Immu-
nol. 200:1016–1026. https:// doi .org/ 10 .4049/ jimmunol .1701177
Zak, D.E., A. Penn-Nicholson, T.J. Scriba, E. Thompson, S. Suliman, L.M. 
Amon, H. Mahomed, M. Erasmus, W. Whatney, G.D. Hussey, et al. ACS 
and GC6-74 cohort study groups. 2016. A blood RNA signature for tuber-
culosis disease risk: a prospective cohort study. Lancet. 387:2312–2322. 
https:// doi .org/ 10 .1016/ S0140 -6736(15)01316 -1
Zarogoulidis, P., I. Kioumis, N. Papanas, K. Manika, T. Kontakiotis, A. Papa-
gianis, and K. Zarogoulidis. 2012. The effect of combination IFN-al-
pha-2a with usual antituberculosis chemotherapy in non-responding 
tuberculosis and diabetes mellitus: a case report and review of the lit-
erature. J. Chemother. 24:173–177. https:// doi .org/ 10 .1179/ 1973947812Y 
.0000000005
Zhang, G., N.A. deWeerd, S.A. Stifter, L. Liu, B. Zhou, W. Wang, Y. Zhou, B. 
Ying, X. Hu, A.Y. Matthews, et al. 2018. A proline deletion in IFN AR1 
impairs IFN-signaling and underlies increased resistance to tubercu-
losis in humans. Nat. Commun. 9:85. https:// doi .org/ 10 .1038/ s41467 -017 
-02611 -z
Zhang, X., D. Bogunovic, B. Payelle-Brogard, V. Francois-Newton, S.D. Speer, 
C. Yuan, S. Volpi, Z. Li, O. Sanal, D. Mansouri, et al. 2015. Human intra-
cellular ISG15 prevents interferon-α/β over-amplification and auto-in-
flammation. Nature. 517:89–93. https:// doi .org/ 10 .1038/ nature13801
